Bioinformatic design and optimization of inhibitory peptides for Tropomyosin receptor kinase B in U266 cell line

Authors

marzieh kafshdouziamin1, H Rahimi2, N Gheibi,*, M karimipour2
1Qazvin University
2pasteur institution
*Corresponding Author: Email: [email protected]

Journal of Inflammatory Diseases:Vol. 17, issue 5; 4-9
Published online:Feb 13, 2014
Article type:Research Article
How to Cite:kafshdouziamin M, Rahimi H, Gheibi N, karimipour M. Bioinformatic design and optimization of inhibitory peptides for Tropomyosin receptor kinase B in U266 cell line. J Inflamm Dis. 2024;17(5):e155776. doi:

Abstract

  Background: Tropomyosin receptor kinase B (TRK B) is one of the oncogene agents.   Objective: The aim of this study was to design and optimize inhibitory peptides for TRK B in U266 cell line .   Methods: This study was conducted in Qazvin University of Medical Sciences during 2012. After generating the peptides library using sequence tolerance method and optimizing energy of peptides employing backrub protocol in Rosetta 3.3 software package, the most stable peptides were selected based on the energy scores in R package. Prediction of the three-dimensional structure of the peptides was performed using the molecular dynamic simulation . Peptides-TRK B docking was evaluated by HADDOCK web server . The most stable peptides were designed and their cytotoxicity effects on U266 cells were investigated by the MTT assay .   Findings: The designed peptides were stable in terms of energy and structure and had high affinity for binding to TRK B . For measuring cell survival during 24 hours treatment of U266 cell line with these peptides, t he half maximal inhibitory concentration (IC50 % ) was obtained 350.2 and 199.5 nM for peptide one and two, respectively.   Conclusion: With regards to the results, it seems that TRK B inhibition can block cancer growth in this cell line.     Keywords: Brain-Derived Neurotrophic Factor, Tropomyosin Receptor Kinase B , Peptides, Oncogenes , Computer Simulation   

Copyright

© 2024, Journal of Inflammatory Diseases. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

Similar Articles

25
May
2026
In silico Identification of Natural Compounds as Potential TrkA Inhibitors for Anticancer Drug Development

In silico Identification of Natural Compounds as Potential TrkA Inhibitors for Anticancer Drug Development

Mujtaba Fadhil,
Dhurgham Al-Fahad,
Faizul Azam,
Asadollah Asadi

Fadhil M, Al-Fahad D, Azam F, Asadi A. In silico Identification of Natural Compounds as Potential TrkA Inhibitors for Anticancer Drug Development. Iran J Pharm Res. 2026;25(1):e166946. doi: https://doi.org/10.5812/ijpr-166946

3
Dec
2023
Evaluation and Simulation of Docking Peptide Labeled with Technetium-99m (Tc-99m) with Human Epidermal Growth Factor Receptor 2 (HER2) in HER2-Positive Breast Cancer Cells

Evaluation and Simulation of Docking Peptide Labeled with Technetium-99m (Tc-99m) with Human Epidermal Growth Factor Receptor 2 (HER2) in HER2-Positive Breast Cancer Cells

Mohammad Mehdi Reyhani,
Amir Abbas Minaeefar,
Fereshteh Dadfar,
Kourosh Bamdad

Reyhani MM, Minaeefar AA, Dadfar F, Bamdad K. Evaluation and Simulation of Docking Peptide Labeled with Technetium-99m (Tc-99m) with Human Epidermal Growth Factor Receptor 2 (HER2) in HER2-Positive Breast Cancer Cells. Jentashapir J Cell Mol Biol. 2023;14(4):e139817. doi: https://doi.org/10.5812/jjcmb-139817

15
Feb
2026
Innovative Peptide Therapeutics for SARS-CoV-2: Design, Docking, and Functional Analysis

Innovative Peptide Therapeutics for SARS-CoV-2: Design, Docking, and Functional Analysis

Samaneh Karimkhanilouei,
Saeid Ghorbian,
Sanaz Mahmazi,
Changiz Ahmadizadeh,
Keivan Nedaei

Karimkhanilouei S, Ghorbian S, Mahmazi S, Ahmadizadeh C, Nedaei K. Innovative Peptide Therapeutics for SARS-CoV-2: Design, Docking, and Functional Analysis. Iran J Pharm Res. 2026;25(1):e160762. doi: https://doi.org/10.5812/ijpr-160762

22
Feb
2025
Design and Characterization of Ricin Based Immunotoxins Against EPHA2 Receptor for Breast Cancer Therapy: An In-Silico Study

Design and Characterization of Ricin Based Immunotoxins Against EPHA2 Receptor for Breast Cancer Therapy: An In-Silico Study

Atefeh Faraz,
Jafar Amani,
Sedigheh Arbabian,
Shohreh Zare Karizi,
Maryam Bikhof Torbati

Faraz A, Amani J, Arbabian S, Zare Karizi S, Bikhof Torbati M. Design and Characterization of Ricin Based Immunotoxins Against EPHA2 Receptor for Breast Cancer Therapy: An In-Silico Study. Iran J Pharm Res. 2025;24(1):e151574. doi: https://doi.org/10.5812/ijpr-151574

11
Jun
2019

Construction, Expression, and Purification of p28 as a Cell-Penetrating Peptide ‎with Anticancer Effects on Burkitt’s Lymphoma Cell Line

Haniyeh Abuei,
Abbas Behzad Behbahani,
Gholamreza Rafiei Dehbidi,
Mohammad Pirouzfar,
Farahnaz Zare,
Ali Farhadi

Abuei H, Behzad Behbahani A, Rafiei Dehbidi G, Pirouzfar M, Zare F, et al. Construction, Expression, and Purification of p28 as a Cell-Penetrating Peptide ‎with Anticancer Effects on Burkitt’s Lymphoma Cell Line. Shiraz E-Med J. 2019;20(7):e85190. doi: https://doi.org/10.5812/semj.85190

More by these authors

marzieh kafshdouziaminPubMedScholar
M karimipourPubMedScholar
Share
Cited by
Metrics